IHC staining revealed a marked decrease in the expression levels of ADAR1, BRCA2, and Ki67 in the tumours of the combination treatment group (Figure 6F), suggesting that targeting ADAR1 alongside cisplatin treatment can significantly impair cell proliferation. The gene discussed is BRCA2; the disease is neoplasm.